These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
177 related articles for article (PubMed ID: 16969634)
1. Decreased protein S activity is related to the disease activity of Behcet's disease. Kwon SR; Lim MJ; Park SG; Moon YS; Park W Rheumatol Int; 2006 Nov; 27(1):39-43. PubMed ID: 16969634 [TBL] [Abstract][Full Text] [Related]
2. Increased serum interleukin-32 levels in patients with Behçet's disease. Ha YJ; Park JS; Kang MI; Lee SK; Park YB; Lee SW Int J Rheum Dis; 2018 Dec; 21(12):2167-2174. PubMed ID: 28378461 [TBL] [Abstract][Full Text] [Related]
3. Serum MMP-2 and MMP-9 in patients with Behçet's disease: do their higher levels correlate to vasculo-Behçet's disease associated with aneurysm formation? Pay S; Abbasov T; Erdem H; Musabak U; Simsek I; Pekel A; Akdogan A; Sengul A; Dinc A Clin Exp Rheumatol; 2007; 25(4 Suppl 45):S70-5. PubMed ID: 17949555 [TBL] [Abstract][Full Text] [Related]
4. The status of serum vitamin D in patients with active Behcet's disease compared with controls. Khabbazi A; Rashtchizadeh N; Ghorbanihaghjo A; Hajialiloo M; Ghojazadeh M; Taei R; Kolahi S Int J Rheum Dis; 2014 May; 17(4):430-4. PubMed ID: 24118939 [TBL] [Abstract][Full Text] [Related]
5. Could be serum uric acid a risk factor for thrombosis and/or uveitis in Behcet's disease? Atıl A; Deniz A Vascular; 2018 Aug; 26(4):378-386. PubMed ID: 29360007 [TBL] [Abstract][Full Text] [Related]
6. Serum anti-lysozyme is associated with disease activity of Behçet's disease. Park JS; Kang MI; Ha YJ; Song JJ; Park YB; Lee SK; Lee SW Int J Rheum Dis; 2017 Feb; 20(2):261-268. PubMed ID: 26890818 [TBL] [Abstract][Full Text] [Related]
7. High mobility group box 1 serum levels are increased in Behçet's disease, but not associated with disease activity or disease manifestations. de Souza AW; Perazzio SF; de França NR; Andrade LE; Bijl M; Westra J; Kallenberg CG Rheumatology (Oxford); 2015 Dec; 54(12):2151-5. PubMed ID: 26170374 [TBL] [Abstract][Full Text] [Related]
8. Neutrophil/lymphocyte ratio and mean platelet volume in Behçet's disease. Balkarli A; Kucuk A; Babur H; Erbasan F Eur Rev Med Pharmacol Sci; 2016 Jul; 20(14):3045-50. PubMed ID: 27460734 [TBL] [Abstract][Full Text] [Related]
9. Homocysteine: an activity marker in Behçet's disease? Sarican T; Ayabakan H; Turkmen S; Kalaslioglu V; Baran F; Yenice N J Dermatol Sci; 2007 Feb; 45(2):121-6. PubMed ID: 17182219 [TBL] [Abstract][Full Text] [Related]
10. Serum Interleukin-33 in Behcet's Disease: Its Relation to Disease Activity and Clinical Manifestations. Fawzy RM; Said EA; Mohamed SM; Fouad NA; Akl EM Egypt J Immunol; 2015 Jun; 22(2):1-8. PubMed ID: 28502139 [TBL] [Abstract][Full Text] [Related]
11. The relationship of serum VEGF and sVEGFR-1 levels with vascular involvement in patients with Behçet's disease. Sertoglu E; Omma A; Yucel C; Colak S; Sandıkcı SC; Ozgurtas T Scand J Clin Lab Invest; 2018 Oct; 78(6):443-449. PubMed ID: 30015524 [TBL] [Abstract][Full Text] [Related]
12. Comparison of existing disease activity indices in the follow-up of patients with Behçet's disease. Shahram F; Khabbazi A; Nadji A; Ziaie N; Banihashemi AT; Davatchi F Mod Rheumatol; 2009; 19(5):536-41. PubMed ID: 19590934 [TBL] [Abstract][Full Text] [Related]
13. Protein S deficiency and antibodies to protein S in patients with Behçet's disease. Guermazi S; Hamza M; Dellagi K Thromb Res; 1997 May; 86(3):197-204. PubMed ID: 9175241 [TBL] [Abstract][Full Text] [Related]
14. Do hemorheological alterations play any role in the development of thrombotic events in Behçet's disease? Vayá A; Ricart J; Todolí J; Micó L; Contreras T; Aznar J Clin Hemorheol Microcirc; 2004; 30(3-4):411-4. PubMed ID: 15258375 [TBL] [Abstract][Full Text] [Related]
15. Serum angiostatin levels in patients with Behçet's disease: does angiogenesis play a role in the pathogenesis of Behçet's disease? Keskin D; Keskin G; Inal A; Ozışık L Acta Clin Belg; 2014 Aug; 69(4):246-50. PubMed ID: 25012748 [TBL] [Abstract][Full Text] [Related]
16. Serum GDF-15 level in Behçet's disease: relationships between disease activity and clinical parameters. Sarıyıldız MA; Yazmalar L; Batmaz İ; Alpaycı M; Burkan YK; Sula B; Kaplan İ; Yıldız M; Akar ZA; Bozkurt M Int J Dermatol; 2016 Nov; 55(11):1289-1294. PubMed ID: 27206990 [TBL] [Abstract][Full Text] [Related]
17. Validation and reliability of a Behcet's Syndrome Activity Scale in Korea. Choi HJ; Seo MR; Ryu HJ; Baek HJ Korean J Intern Med; 2016 Jan; 31(1):170-5. PubMed ID: 26767871 [TBL] [Abstract][Full Text] [Related]
18. Serum levels of alpha-1 acid glycoprotein and pentraxin 3 in patients with Behçet's disease and relationship with disease activity. Yazmalar L; Batmaz İ; Sula B; Alpaycı M; Aydın F; Türkçü F; Yıldız M; Kaplan İ; Bozkurt M; Dağlı AZ; Burkan YK; Sarıyıldız MA Int J Dermatol; 2015 Oct; 54(10):e394-400. PubMed ID: 26147939 [TBL] [Abstract][Full Text] [Related]
19. Serum galectin-3 levels in patients with Behçet's disease: association with disease activity over a long-term follow-up. Özden MG; Caycı YT; Tekin H; Çoban AY; Aydın F; Sentürk N; Bek Y; Cantürk T; Turanlı AY J Eur Acad Dermatol Venereol; 2011 Oct; 25(10):1168-73. PubMed ID: 21214630 [TBL] [Abstract][Full Text] [Related]
20. Anti-alpha-enolase antibodies in Behçet's disease: a marker of mucocutaneous and articular disease activity? Prado LL; Goncalves CR; Viana VT; Saad CGS; Bonfa E Clin Exp Rheumatol; 2018; 36(6 Suppl 115):28-32. PubMed ID: 29465373 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]